D. M. Goldenberg, F. De-land, E. Kim, S. Bennett, F. J. Primus et al., Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1386, 1978.
DOI : 10.1056/NEJM197806222982503

G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1042/bj1280427

H. Koprowski, Z. Steplewski, D. Herlyn, and M. Herlyn, Study of antibodies against human melanoma produced by somatic cell hybrids., Proc. Natl. Acad. Sci, pp.3405-3409, 1978.
DOI : 10.1073/pnas.75.7.3405

M. Herlyn, Z. Steplewski, D. Herlyn, and H. Koprowski, Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies., Proc. Natl. Acad. Sci. USA 1979, pp.1438-1442
DOI : 10.1073/pnas.76.3.1438

B. A. Khaw, J. Cooney, T. Edgington, and H. W. Strauss, Differences in Experimental Tumor Localization of Dual-Labeled Monoclonal Antibody, J. Nucl. Med, vol.27, pp.1293-1299, 1986.

J. Barbet, P. Peltier, S. Bardet, J. P. Vuillez, I. Bachelot et al., Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium Bispecific Antibody, J. Nucl. Med, vol.39, pp.1172-1178, 1998.

J. Teillaud, Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges, Expert Opinion on Biological Therapy, vol.5, issue.sup1, pp.15-27, 2005.
DOI : 10.1073/pnas.96.5.1898

O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman, Immunotherapy of Non-Hodgkin's Lymphomas. Hematol, Am. Soc. Hematol. Educ. Program, pp.221-240, 2001.

D. J. Slamon, B. Leyland-jones, S. Shak, H. Fuchs, V. Paton et al., Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross et al., Radioimmunotherapy with Iodine (131)I Tositumomab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results and Long-Term Follow-up of the University of Michigan Experience, Blood, vol.96, pp.1259-1266, 2000.

O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu et al., A Phase I/II Trial of Iodine-131-Tositumomab (anti-CD20, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation for Relapsed B-Cell Lymphomas, pp.2934-2942, 2000.

F. Kraeber-bodéré, C. Bodet-milin, C. Rousseau, T. Eugène, and A. Pallardy,

T. Carlier, L. Ferrer, J. Gaschet, and F. Davodeau, Radioimmunoconjugates for the Treatment of Cancer, Semin. Oncol, vol.41, pp.613-622, 2014.

O. C. Boerman and W. J. Oyen, Immuno-PET of Cancer: A Revival of Antibody Imaging, Journal of Nuclear Medicine, vol.52, issue.8, pp.1171-1172, 2011.
DOI : 10.2967/jnumed.111.089771

G. A. Van-dongen, A. J. Poot, and D. J. Vugts, PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET, Tumor Biology, vol.353, issue.Suppl 1, pp.607-615, 2012.
DOI : 10.1056/NEJMoa050753

J. Barbet, M. Bardiès, M. Bourgeois, J. Chatal, M. Chérel et al., Radiolabeled Antibodies for Cancer Imaging and Therapy, Methods Mol. Biol, vol.907, pp.681-697, 2012.
DOI : 10.1007/978-1-61779-974-7_38

J. Pouget, I. Navarro-teulon, M. Bardiès, N. Chouin, G. Cartron et al., Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011.
DOI : 10.1158/1078-0432.CCR-1004-0023

S. Demaria, B. Ng, M. L. Devitt, J. S. Babb, N. Kawashima et al., Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated, International Journal of Radiation Oncology*Biology*Physics, vol.58, issue.3, pp.862-870, 2004.
DOI : 10.1016/j.ijrobp.2003.09.012

C. Bodet-milin, L. Ferrer, A. Pallardy, T. Eugène, A. Rauscher et al., Kraeber-Bodéré, F. Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma. Front, Oncol, vol.2013, issue.3, p.177

T. Liersch, J. Meller, B. Kulle, T. M. Behr, P. Markus et al., I-Labetuzumab After Salvage Resection of Colorectal Metastases in the Liver: Five-Year Safety and Efficacy Results, Journal of Clinical Oncology, vol.23, issue.27, pp.6763-6770, 2005.
DOI : 10.1200/JCO.2005.18.622

S. T. Tagawa, H. Beltran, S. Vallabhajosula, S. J. Goldsmith, J. Osborne et al., Anti-prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer, Cancer, vol.23, issue.suppl 10 pt 2, pp.1075-1083, 2010.
DOI : 10.1016/1078-1439(95)00004-2

D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J. Chatal, Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006.
DOI : 10.1200/JCO.2005.03.8471

J. Chatal, L. Campion, F. Kraeber-bodéré, S. Bardet, and J. Vuillez,

V. Rohmer, C. Chang, R. M. Sharkey, and D. M. Goldenberg, Survival Improvement in Patients with Medullary Thyroid Carcinoma Who Undergo Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study with the French Endocrine Tumor Group

, J. Clin. Oncol, vol.24, pp.1705-1711, 2006.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, L. Ferrer, A. Faivre-chauvet et al., Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131 I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial, J. Nucl. Med, vol.47, pp.247-255, 2006.

P. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. Vuillez et al., Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012.
DOI : 10.2967/jnumed.111.101865

URL : https://hal.archives-ouvertes.fr/hal-00932253

R. Schoffelen, O. C. Boerman, D. M. Goldenberg, R. M. Sharkey, C. M. Van-herpen et al., Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, British Journal of Cancer, vol.20, issue.4, pp.934-942, 2013.
DOI : 10.1200/JCO.2002.11.076

A. J. Ocean, K. L. Pennington, M. J. Guarino, A. Sheikh, T. Bekaii-saab et al., Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer, Cancer, vol.6, issue.suppl, pp.5497-5506, 2012.
DOI : 10.1016/S1040-8428(00)00136-0

J. Chatal, F. Davodeau, M. Cherel, and J. Barbet, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009.
DOI : 10.4103/0973-1482.55139

O. 'donoghue, J. A. Bardiès, M. Wheldon, and T. E. , Relationships between Tumor Size and Curability for Uniformly Targeted Therapy with Beta-Emitting Radionuclides, J. Nucl. Med, vol.36, pp.1902-1909, 1995.

F. Morschhauser, J. Radford, A. Van-hoof, U. Vitolo, P. Soubeyran et al., Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008.
DOI : 10.1200/JCO.2008.17.2015

F. Morschhauser, J. Radford, A. Van-hoof, B. Botto, A. Z. Rohatiner et al., 90 Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results after a Median Follow-up of 7.3 Years from the International, Randomized, Phase III First-LineIndolent Trial, J. Clin. Oncol, pp.31-1977, 2013.

V. Boudousq, S. Ricaud, V. Garambois, C. Bascoul-mollevi, S. Boutaleb et al., Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies, Journal of Nuclear Medicine, vol.51, issue.11, pp.1748-1755, 2010.
DOI : 10.2967/jnumed.110.080226

URL : https://hal.archives-ouvertes.fr/inserm-00531603

L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-mollevi, V. Boudousq et al., Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2041, 2009.
DOI : 10.2967/jnumed.109.066993

URL : https://hal.archives-ouvertes.fr/inserm-00442929

G. Sgouros, J. C. Roeske, M. R. Mcdevitt, S. Palm, B. J. Allen et al., Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide Therapy, MIRD Pamphlet No. J. Nucl. Med, vol.22, issue.51, pp.311-328, 2010.

D. G. Medvedev, L. F. Mausner, G. E. Meinken, S. O. Kurczak, H. Schnakenberg et al., Development of a large scale production of 67Cu from 68Zn at the high energy proton accelerator: Closing the 68Zn cycle, Development of a Large Scale Production of 67 Cu from 68 Zn at the High Energy Proton Accelerator: Closing the 68 Zn Cycle, pp.423-429, 2012.
DOI : 10.1016/j.apradiso.2011.10.007

M. Chérel, F. Davodeau, F. Kraeber-bodéré, and J. Chatal, Current Status and Perspectives in Alpha Radioimmunotherapy, Q. J. Nucl. Med. Mol. Imaging, vol.50, pp.322-329, 2006.

P. J. Fraker, J. C. Speck, and . Jr, Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, Biochemical and Biophysical Research Communications, vol.80, issue.4, pp.849-857, 1978.
DOI : 10.1016/0006-291X(78)91322-0

G. Vaidyanathan, E. Jestin, T. Olafsen, A. M. Wu, and M. R. Zalutsky, Evaluation of an anti-p185HER2 (scFv-CH2-CH3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-d-GEEEK, Nuclear Medicine and Biology, vol.36, issue.6, pp.671-680, 2009.
DOI : 10.1016/j.nucmedbio.2009.04.002

M. W. Brechbiel, Bifunctional Chelates for Metal Nuclides, Q. J. Nucl. Med. Mol. Imaging, vol.52, pp.166-173, 2008.

O. Donnell, R. T. Denardo, S. J. Miers, L. A. Lamborn, K. R. Kukis et al., Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and90yttrium-DOTA-peptide-ChL6, The Prostate, vol.159, issue.1, pp.27-37, 2002.
DOI : 10.1016/S0022-5347(01)63990-9

C. M. Richman, S. J. Denardo, R. T. Donnell, A. Yuan, S. Shen et al., High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody, Clinical Cancer Research, vol.11, issue.16, pp.5920-5927, 2005.
DOI : 10.1158/1078-0432.CCR-05-0211

R. F. Meredith, A. J. Bueschen, M. B. Khazaeli, W. E. Plott, W. E. Grizzle et al., Treatment of Metastatic Prostate Carcinoma with Radiolabeled Antibody CC49, J. Nucl. Med, vol.35, pp.1017-1022, 1994.

R. L. Sokoloff, K. C. Norton, C. L. Gasior, K. M. Marker, and L. S. Grauer, A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine, The Prostate, vol.55, issue.2, pp.150-157, 2000.
DOI : 10.1016/1078-1439(95)00004-2

G. L. Wright, . Jr, C. Haley, M. L. Beckett, and P. Schellhammer, Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues, Urologic Oncology: Seminars and Original Investigations, vol.1, issue.1, pp.18-28, 1995.
DOI : 10.1016/1078-1439(95)00002-Y

R. S. Israeli, C. T. Powell, J. G. Corr, W. R. Fair, and W. Heston, Expression of the Prostate-Specific Membrane Antigen, Cancer Res, vol.54, pp.1807-1811, 1994.

R. S. Israeli, C. T. Powell, W. R. Fair, and W. Heston, Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen, Cancer Res, vol.53, pp.227-230, 1993.

J. S. Horoszewicz, E. Kawinski, and G. P. Murphy, Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients, Anticancer Res, vol.7, pp.927-935, 1987.

D. G. Bostwick, A. Pacelli, M. Blute, P. Roche, and G. P. Murphy, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma, Cancer, vol.49, issue.11, pp.2256-2261, 1998.
DOI : 10.1016/S0090-4295(97)00175-1

H. Liu, A. K. Rajasekaran, P. Moy, Y. Xia, S. Kim et al., Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen, Cancer Res, vol.58, pp.4055-4060, 1998.

H. Liu, P. Moy, S. Kim, Y. Xia, A. Rajasekaran et al., Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium, Cancer Res, vol.57, pp.3629-3634, 1997.

N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula et al., Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.21, pp.4591-4601, 2005.
DOI : 10.1200/JCO.2005.05.160

S. T. Tagawa, M. I. Milowsky, M. Morris, S. Vallabhajosula, and P. Christos,

J. Osborne, S. J. Goldsmith, S. Larson, and N. P. Taskar, Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer, Clin. Cancer Res. 2013, vol.19, pp.5182-5191

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc. Natl. Acad. Sci, pp.6841-6846, 2006.
DOI : 10.1158/0008-5472.CAN-05-0420

R. M. Sharkey, W. J. Mcbride, H. Karacay, K. Chang, G. L. Griffiths et al., A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody, Cancer Res, vol.63, pp.354-363, 2003.

W. J. Mcbride, P. Zanzonico, R. M. Sharkey, C. Norén, H. Karacay et al., Bispecific Antibody Pretargeting PET (immunoPET) with an 124 I-Labeled Hapten-Peptide, J. Nucl. Med, vol.47, pp.1678-1688, 2006.

W. J. Mcbride, R. M. Sharkey, H. Karacay, C. A. Souza, E. A. Rossi et al., A Novel Method of 18F Radiolabeling for PET, Journal of Nuclear Medicine, vol.50, issue.6, pp.991-998, 2009.
DOI : 10.2967/jnumed.108.060418

R. Schoffelen, W. T. Van-der-graaf, G. Franssen, R. M. Sharkey, and D. M. Goldenberg,

W. J. Mcbride, E. A. Rossi, A. Eek, W. J. Oyen, and O. C. Boerman, Pretargeted 177 Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice, J. Nucl. Med, vol.51, pp.1780-1787, 2010.

R. Schoffelen, W. Van-der-weg, E. P. Visser, D. M. Goldenberg, R. M. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Suppl 1, pp.1593-1602, 2014.
DOI : 10.1089/cbr.2006.21.106

E. Frampas, C. Maurel, P. Remaud-le-saëc, T. Mauxion, A. Faivre-chauvet et al., Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide, European Journal of Nuclear Medicine and Molecular Imaging, vol.14, issue.9, pp.2153-2164, 2011.
DOI : 10.1158/1078-0432.CCR-07-2031

S. J. Denardo, G. L. Denardo, D. L. Kukis, S. Shen, L. A. Kroger et al., Radiation Dosimetry, Toxicity and Tumor Regression in Patients with Lymphoma, Mausner, L.F.; et al. 67 Cu-2IT-BAT-Lym-1 Pharmacokinetics, pp.302-310, 1999.

G. L. Denardo, S. J. Denardo, R. T. Donnell, L. A. Kroger, D. L. Kukis et al., Are Radiometal-Labeled Antibodies Better Than Iodine-131???Labeled Antibodies: Comparative Pharmacokinetics and Dosimetry of Copper-67???, Iodine-131???, and Yttrium-90???Labeled Lym-1 Antibody in Patients with Non-Hodgkin's Lymphoma, Clinical Lymphoma, vol.1, issue.2, pp.118-126, 2000.
DOI : 10.3816/CLM.2000.n.010

A. B. Delaloye, B. Delaloye, F. Buchegger, C. A. Vogel, M. Gillet et al., Comparison of Copper-67-and Iodine-125-Labeled Anti-CEA Monoclonal Antibody Biodistribution in Patients with Colorectal Tumors, J. Nucl. Med, vol.38, pp.847-853, 1997.

L. Pietrelli, L. F. Mausner, and K. L. Kolsky, Separation of carrier-free47Sc from titanium targets, Journal of Radioanalytical and Nuclear Chemistry Articles, vol.13, issue.2, pp.335-345, 1992.
DOI : 10.1016/S0301-4770(08)60969-0

C. Müller, M. Bunka, J. Reber, C. Fischer, K. Zhernosekov et al., Promises of Cyclotron-Produced 44Sc as a Diagnostic Match for Trivalent ??--Emitters: In Vitro and In Vivo Study of a 44Sc-DOTA-Folate Conjugate, Journal of Nuclear Medicine, vol.54, issue.12, pp.2168-2174, 2013.
DOI : 10.2967/jnumed.113.123810

C. Müller, K. Zhernosekov, U. Köster, K. Johnston, H. Dorrer et al., A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for ??- and ??--Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative, Journal of Nuclear Medicine, vol.53, issue.12, pp.1951-1959, 2012.
DOI : 10.2967/jnumed.112.107540

J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. Mcdevitt, R. D. Finn et al., , pp.1233-1239, 2002.

M. Chérel, S. Gouard, J. Gaschet, C. Saï-maurel, F. Bruchertseifer et al., 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.1597-1604, 2013.
DOI : 10.2967/jnumed.112.111997

S. Supiot, A. Faivre-chauvet, O. Couturier, M. F. Heymann, N. Robillard et al., Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma, Cancer, vol.335, issue.S4, pp.1202-1209, 2002.
DOI : 10.1002/cncr.10286

M. R. Mcdevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt et al., Tumor Therapy with Targeted Atomic Nanogenerators, Science, vol.294, issue.5546, pp.1537-1540, 2001.
DOI : 10.1126/science.1064126

M. Miederer, M. R. Mcdevitt, G. Sgouros, K. Kramer, N. V. Cheung et al., Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225 Ac-HuM195, in Nonhuman Primates, J. Nucl. Med, vol.45, pp.129-137, 2004.

R. Meredith, J. Torgue, S. Shen, D. R. Fisher, E. Banaga et al., Dose Escalation and Dosimetry of First-in-Human ? Radioimmunotherapy with 212

P. , J. Nucl. Med, vol.2014, issue.55, pp.1636-1642

R. F. Meredith, J. Torgue, M. T. Azure, S. Shen, S. Saddekni et al., Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients, Cancer Biotherapy & Radiopharmaceuticals, vol.29, issue.1, pp.12-17
DOI : 10.1089/cbr.2013.1531

J. Schwartz, J. S. Jaggi, J. A. O-'donoghue, S. Ruan, M. Mcdevitt et al., Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody, Physics in Medicine and Biology, vol.56, issue.3, pp.721-733, 2011.
DOI : 10.1088/0031-9155/56/3/012

H. Heyerdahl, N. Abbas, K. Sponheim, C. Mollatt, Ø. Bruland et al., Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice, Current Radiopharmaceuticals, vol.6, issue.2, pp.106-116
DOI : 10.2174/18744710113069990018

V. Boudousq, L. Bobyk, M. Busson, V. Garambois, M. Jarlier et al., Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb, PLoS ONE, vol.49, issue.7, p.69613, 2013.
DOI : 10.1371/journal.pone.0069613.g007

M. R. Zalutsky, P. K. Garg, H. S. Friedman, and D. D. Bigner, Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity., Proc. Natl. Acad. Sci. USA 1989, pp.7149-7153
DOI : 10.1073/pnas.86.18.7149

C. J. Reist, C. F. Foulon, K. Alston, D. D. Bigner, and M. R. Zalutsky, Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate, Nuclear Medicine and Biology, vol.26, issue.4, pp.405-411, 1999.
DOI : 10.1016/S0969-8051(98)00120-6

J. J. Orozco, T. Bäck, A. Kenoyer, E. R. Balkin, D. K. Hamlin et al., Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, issue.18, pp.3759-3767, 2013.
DOI : 10.1182/blood-2012-11-467035

URL : http://www.bloodjournal.org/content/bloodjournal/121/18/3759.full.pdf

M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman et al., Z

, At: Treatment of Recurrent Brain Tumor Patients with 211 At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, J. Nucl. Med, vol.49, pp.30-38, 2008.

H. Andersson, E. Cederkrantz, T. Bäck, C. Divgi, J. Elgqvist et al., et al. Intraperitoneal Alpha-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of (211)At-MX35 F(ab'), p.2

I. Phase and . Study, J. Nucl. Med, vol.50, pp.1153-1160, 2009.

S. Stute, D. Benoit, A. Martineau, N. S. Rehfeld, and I. Buvat, A method for accurate modelling of the crystal response function at a crystal sub-level applied to PET reconstruction, Physics in Medicine and Biology, vol.56, issue.3, pp.793-809, 2011.
DOI : 10.1088/0031-9155/56/3/016

W. W. Moses, Recent advances and future advances in time-of-flight PET, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol.580, issue.2, pp.919-924, 2007.
DOI : 10.1016/j.nima.2007.06.038

T. K. Lewellen, Recent developments in PET detector technology, Physics in Medicine and Biology, vol.53, issue.17, pp.287-317, 2008.
DOI : 10.1088/0031-9155/53/17/R01

S. M. Knowles and A. M. Wu, Advances in Immuno???Positron Emission Tomography: Antibodies for Molecular Imaging in Oncology, Journal of Clinical Oncology, vol.30, issue.31, pp.3884-3892, 2012.
DOI : 10.1200/JCO.2012.42.4887

G. A. Van-dongen, G. W. Visser, M. N. Lub-de-hooge, and E. G. De-vries, Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, Perk, L.R. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, pp.1379-1389, 2007.
DOI : 10.1634/theoncologist.12-12-1379

S. Heskamp, H. W. Van-laarhoven, J. D. Molkenboer-kuenen, G. M. Franssen, Y. M. Versleijen-jonkers et al., ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model, Journal of Nuclear Medicine, vol.51, issue.10, pp.1565-1572, 2010.
DOI : 10.2967/jnumed.110.075648

R. P. Baum, V. Prasad, D. Müller, C. Schuchardt, A. Orlova et al., Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules, Journal of Nuclear Medicine, vol.51, issue.6, pp.892-897, 2010.
DOI : 10.2967/jnumed.109.073239

R. Schoffelen, R. M. Sharkey, D. M. Goldenberg, G. Franssen, W. J. Mcbride et al., Pretargeted Immuno-Positron Emission Tomography Imaging of Carcinoembryonic Antigen-Expressing Tumors with a Bispecific Antibody and a 68Ga- and 18F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts, Molecular Cancer Therapeutics, vol.9, issue.4, pp.1019-1027, 2010.
DOI : 10.1158/1535-7163.MCT-09-0862

P. K. Börjesson, Y. W. Jauw, R. Boellaard, R. De-bree, E. F. Comans et al., Performance of Immuno-Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients, Clinical Cancer Research, vol.12, issue.7, pp.2133-2140, 2006.
DOI : 10.1158/1078-0432.CCR-05-2137

L. R. Perk, M. Stigter-van-walsum, G. W. Visser, R. W. Kloet, M. J. Vosjan et al., Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30, European Journal of Nuclear Medicine and Molecular Imaging, vol.48, issue.Suppl 1, pp.1857-1867, 2008.
DOI : 10.1007/s00259-008-0774-5

C. R. Divgi, R. G. Uzzo, C. Gatsonis, R. Bartz, S. Treutner et al., Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial, Journal of Clinical Oncology, vol.31, issue.2, pp.31-187, 2013.
DOI : 10.1200/JCO.2011.41.2445

C. R. Divgi, N. Pandit-taskar, A. A. Jungbluth, V. E. Reuter, M. Gönen et al., Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, The Lancet Oncology, vol.8, issue.4, pp.304-310, 2007.
DOI : 10.1016/S1470-2045(07)70044-X

D. A. Pryma, J. A. O-'donoghue, J. L. Humm, A. A. Jungbluth, L. J. Old et al., Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250, Journal of Nuclear Medicine, vol.52, issue.4, pp.535-540, 2011.
DOI : 10.2967/jnumed.110.083295

K. Tamura, H. Kurihara, K. Yonemori, H. Tsuda, J. Suzuki et al., Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, J. Nucl. Med, vol.64, issue.54, pp.1869-1875, 2013.
DOI : 10.2967/jnumed.112.118612

URL : http://jnm.snmjournals.org/content/54/11/1869.full.pdf

S. M. Cheal, B. Punzalan, M. G. Doran, M. J. Evans, J. R. Osborne et al., Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.52, issue.5, pp.985-994, 2014.
DOI : 10.2967/jnumed.111.095596

B. Zhao, L. H. Schwartz, and S. M. Larson, Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers, Journal of Nuclear Medicine, vol.50, issue.2, pp.239-249, 2009.
DOI : 10.2967/jnumed.108.056655

B. A. Hoeben, J. H. Kaanders, G. M. Franssen, E. G. Troost, P. F. Rijken et al., PET of Hypoxia with 89Zr-Labeled cG250-F(ab')2 in Head and Neck Tumors, Journal of Nuclear Medicine, vol.51, issue.7, pp.1076-1083, 2010.
DOI : 10.2967/jnumed.109.073189

E. C. Dijkers, T. H. Oude-munnink, J. G. Kosterink, A. H. Brouwers, P. L. Jager et al., Lub-de Hooge, M.N.; de Vries, E.G. Biodistribution of, p.89

P. Zr-trastuzumab, Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer, Clin. Pharmacol. Ther, vol.87, pp.586-592, 2010.

J. E. Mortimer, J. R. Bading, D. M. Colcher, P. S. Conti, P. H. Frankel et al., Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET, Journal of Nuclear Medicine, vol.55, issue.1, pp.23-29, 2014.
DOI : 10.2967/jnumed.113.122630

URL : http://jnm.snmjournals.org/content/55/1/23.full.pdf

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license